Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Melinda J GooderhamRonald VenderJeffrey CrowleyH Chih-Ho HongMeghan FeelyAlyssa GarreltsKyoungah SeeBruce KonicekLawrence GreenPublished in: Dermatology and therapy (2024)
gov/ : NCT03573323 (IXORA-R).
Keyphrases